We Don’t Know What We Don’t Know: Understanding Experiences of Underrepresented Adolescents and Young Adults with Cancer in Canada

Summary

Cancer does not discriminate, and we must ensure the voices of all adolescents and young adults (AYAs) impacted by cancer are heard in research, regardless of social/cultural identity and strata.

AYAs impacted by cancer are at risk of experiencing mental health challenges, yet many research studies struggle to engage AYAs who are from under-represented and under-researched groups. These include individuals who identify as Indigenous, racialized, a person with a disability, young men, and/or a member of an 2SLGBTQIA+ community.

Researchers from the University of Calgary are looking to partner with individuals impacted by cancer from under-represented and/or under-researched minority groups to participate in an online focus group or a one-on-one interview. Our goal is to work together with people with lived experience and stakeholders on a study aimed at identifying safe, equitable and culturally-sensitive recruitment strategies for future research studies.

Eligibility

Currently recruiting participants: No

Eligible gender: Male, Female, Transgender, Other

Eligible ages: 15 to 39

Inclusion criteria:

Adolescents and young adults impacted by cancer are eligible if you:
• Are 15-39 years old
• Have been previously diagnosed with cancer
• Identify as a member of an under-represented or under-researched group
• Are Canadian or living in Canada

Stakeholders such as community-based organizations or healthcare are eligible if you:
• Are a stakeholder for Canadian adolescents and young adults from under-represented or under-researched groups
• Are a stakeholder for Canadian adolescents and young adults who have been diagnosed with cancer

Participate

Sorry, this study is not currently accepting new participants.
Browse other research studies.

Additional information

Contact information

Please contact Jenny Duong for more information

Principal investigator:

Fiona Schulte

Clinical trial:

No

REB-ID:

HREBA.CC-22-0126